Click here to view online. Add this email to your safelist.
Farxiga improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
7 November 2022
New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxiga (dapagliflozin) improved symptom burden and health-related quality of life in patients with heart failure (HF) and mildly reduced or preserved ejection fraction (EF) compared with placebo. The results were presented today at the American Heart Association (AHA) Scientific Sessions 2022 in Chicago, Illinois, US, and are currently in press in the Journal of the American College of Cardiology.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
